BioVie (NASDAQ:BIVI) Cut to Sell at Wall Street Zen

BioVie (NASDAQ:BIVI) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

BioVie Trading Down 0.5%

Shares of BioVie stock opened at $1.86 on Friday. The company’s 50-day moving average price is $3.60 and its two-hundred day moving average price is $7.74. BioVie has a 52 week low of $1.42 and a 52 week high of $75.00. The stock has a market cap of $14.01 million, a PE ratio of -0.02 and a beta of 0.66.

Institutional Trading of BioVie

Institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC acquired a new stake in BioVie during the 4th quarter worth about $245,000. Two Sigma Investments LP purchased a new position in BioVie during the 4th quarter valued at about $57,000. Northern Trust Corp purchased a new position in BioVie during the 4th quarter valued at about $34,000. Squarepoint Ops LLC purchased a new position in BioVie during the 4th quarter valued at about $28,000. Finally, Jane Street Group LLC purchased a new position in BioVie during the 2nd quarter valued at about $57,000. Institutional investors and hedge funds own 4.59% of the company’s stock.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.